Loading...
•
Sep 30, 2023
Adverum Q3 2023 Earnings Report
Adverum reported its Q3 2023 financial results and pipeline highlights.
Key Takeaways
Adverum Biotechnologies reported its third quarter financial results, highlighting progress in their LUNA and OPTIC trials for Ixo-vec, and anticipates initial Phase 2 LUNA efficacy and safety data in Q4 2023. The company's cash runway is projected into 2025.
Reported preliminary aflibercept protein levels from the Phase 2 LUNA trial, suggesting both doses are within the therapeutically active range.
Reported OPTIC long-term follow-up data demonstrating substantial, long-term benefit from Ixo-vec through 3 years of follow-up.
Initial Phase 2 LUNA efficacy and safety data is anticipated in Q4 2023.
Cash runway is projected into 2025.
Adverum
Adverum
Forward Guidance
Adverum anticipates preliminary efficacy and safety data from the LUNA trial in Q4 2023 and additional LUNA data, including the 26-week interim analysis, in mid-2024.
Positive Outlook
- Potential benefits of Ixo-vec in the treatment of wet AMD
- Design of the LUNA trial
- Anticipated preliminary efficacy data from the LUNA trial
- Anticipated preliminary safety data from the LUNA trial
- Additional LUNA data, including the 26-week interim analysis, in mid-2024.
Challenges Ahead
- Adverum’s novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials
- Regulatory uncertainties
- Enrollment uncertainties
- The results of early clinical trials not always being predictive of future clinical trials and results
- The potential for future complications or side effects in connection with use of Ixo-vec